Blinatumomab for the treatment of acute lymphoblastic leukemia

Investigational New Drugs

Volumn 33, Issue 6, 2015, Pages 1271-1279

  Kaplan, Jason B ^a,b   Grischenko, Marina ^b   Giles, Francis J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University Feinberg School of Medicine   (United States)

Author keywords

Acute lymphoblastic leukemia; Bispecific T cell engager; Blinatumomab; CD19; Targeted therapy

Indexed keywords

BLINATUMOMAB; CD19 ANTIGEN; CD34 ANTIGEN; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; APHASIA; APOPTOSIS; B LYMPHOCYTE; BRAIN DISEASE; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CONFUSION; CONTINUOUS INFUSION; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DISORIENTATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; EPILEPSY; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNOGLOBULIN DEFICIENCY; INFECTION; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RIGOR; SEIZURE; T LYMPHOCYTE; TREMOR; ANIMAL; CLINICAL TRIAL (TOPIC); PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84947484898     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0289-4     Document Type: Review

References (56)

1. Dores M, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States. Blood 119(1):2001-7
2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9-29
3. Vardiman JW, Arber DA, Brunning RD et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937-51
4. Moorman AV, Harrison CJ, Buck GA et al (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109(8):3189-97
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Lymphoblastic Leukemia [Internet]. NCCN 2014. Available from: http://www.nccn.org/professionals/physician-gls/pdf/all.pdf
6. Thomas DA, O'Brien S, Faderl S et al (2010) Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28(24):3880-9
7. Hoelzer D, Huettmann A, Kaul F et al (2010) Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. ASH Annu Meet Abstr 116(21):170
8. Ribera J-M (2013) Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma 54(1):21-7
9. Pulte D, Redaniel MT, Jansen L, Brenner H, Jeffreys M (2013) Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica 98(2):222-9
10. Pui C-H, Evans WE (2013) A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 50(3):185-96, Elsevier
11. Stock W, La M, Sanford B et al (2008) What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 112(5):1646-54
12. Ten Cate B, de Bruyn M, Wei Y, Bremer E, Helfrich W (2010) Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr Drug Targets 11(1):95-110
13. Bruggemann M, Raff T, Kneba M (2012) Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 120(23):4470-81
14. Fielding AK, Richards SM, Chopra R et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109(3):944-50
15. O'Brien S, Thomas D, Ravandi F et al (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186-91
16. Dombret H, Cluzeau T, Huguet F, Boissel N (2014) Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep. doi: 10.1007/s11899-014-0210-9
17. Wetzler M, Thomas DA, Wang ES et al (2013) Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 13(4):430-4, Elsevier Inc
18. Robak P, Robak T (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 39(8):851-61, Elsevier Ltd
19. Ai J, Advani A (2014) Current status of antibody therapy in ALL. Br J Haematol. doi: 10.1111/bjh.13205, 1-10
20. Advani AS (2013) New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors. Hematol Am Soc Hematol Educ Program 2013:131-7
21. Chevallier P, Huguet F, Raffoux E et al (2014) Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a Phase 2 Study. Haematologica 100(4):e128-31
22. Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509-18
23. Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507-17
24. Depoil D, Fleire S, Treanor BL et al (2008) CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol 9(1):63-72
25. Nadler LM, Anderson KC, Marti G et al (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131:244-50
26. Wang K, Wei G, Liu D (2012) CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1(1):36
27. Carter RH, Fearon DT (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105-7
28. Van Zelm MC, Reisli I, van der Burg M et al (2006) An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 354:1901-12
29. Raponi S, De Propris MS, Intoppa S et al (2011) Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 52(June):1098-107
30. Uckun FM, Jaszcz W, Ambrus JL et al (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71(1):13-29
31. Uckun FM, Manivel C, Arthur D et al (1992) In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 79:2201-14
32. Mitchell P, Lee F-T, Hall C et al (2003) Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies. J Nucl Med 44:1105-12
33. Nagorsen D, Kufer P, Baeuerle PA, Bargou R (2012) Blinatumomab: a historical perspective. Pharmacol Ther 136(3):334-42, Elsevier Inc
34. Zimmerman Z, Maniar T, Nagorsen D (2014) Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy. Int Immunol 27(1):31-7
35. Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314(6012):628-31, England
36. Mack M, Riethmüller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 92(July):7021-5
37. Frankel SR, Baeuerle PA (2013) Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 17(3):385-92, Elsevier Ltd
38. Dreier T, Lorenczewski G, Brandl C et al (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100(6):690-7
39. Hoffmann P, Hofmeister R, Brischwein K et al (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 115(1):98-104
40. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-96
41. Schub A, Nagele V, Zugmaier G, et al (2013) Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). J Clin Oncol (suppl; abstr 7020)
42. Brandl C, Haas C, D'Argouges S et al (2007) The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 56(10):1551-63
43. Dreier T, Baeuerle PA, Fichtner I et al (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 170(8):4397-402
44. Onyx Pharmaceuticals (2015) BLINCYTO (blinatumomab) Prescribing Information
45. Wu B, Hijazi Y, Wolf A, Brandl C, Sun Y-N, Zhu M (2013) Pharmacokinetics (PK) of blinatumomab and its clinical implications. ASCO Meet Abstr 31(15-suppl):3048
46. Nagorsen D, Baeuerle PA (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317(9):1255-60, Elsevier Inc
47. FDA Drug Approval Package [Internet]. [cited 2015 Mar 2]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/125557Orig1s000TOC.cfm
48. Goebeler M-E, Viardot A, Kufer P, Topp MS, Knop S, Mackensen L (2013) Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory Non-Hodgkin's lymphoma. Hematol Oncol 31(Abstract 302):197
49. Locatelli F, Gore L, Zugmaier G, Handgretinger R, Rizzari C, Trippett T (2014) Blinatumomab in pediatric patients with Relapsed/Refractory (R/R) B-cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL): a phase I/II study. Bone Marrow Transplant 37(Abstract PH-P545):S361
50. Topp MS, Kufer P, Gökbuget N et al (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29(18):2493-8
51. Topp MS, Gökbuget N, Zugmaier G et al (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120(26):5185-7
52. Topp MS, Gokbuget N, Zugmaier G et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32(36):4134-40
53. Topp MS, Gökbuget N, Stein AS et al (2014) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 15:57-66
54. Goekbuget N, Dombret H, Bonifacio M et al (2014) BLAST: a confirmatory, single-Arm, phase 2 study of blinatumomab, a Bispecific T-cell Engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor Acute Lymphoblastic Leukemia (ALL). Blood 124(21):Abstract 379
55. Ruella M, Gill S (2015) How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opin Biol Ther 15(6):761-6
56. Thomas X (2014) Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol 16(1):6-7, Elsevier Ltd